Summary of neutralizing samples per IFN-I condition tested
| Sample category . | IFN-α2 1 ng/ml . | IFN-β 1 ng/ml . | IFN-ω 1 ng/ml . | IFN-α2 100 pg/ml . | IFN-ω 200 pg/ml . | Individuals with neutralizing autoAbs . |
|---|---|---|---|---|---|---|
| Danish cohort, N (%) | 0/318 (0.00) | 0/318 (0.00) | 2/318 (0.63) | 0/318 (0.00) | 3/313a (0.96) | 3/318 (0.94) |
| American cohort, N (%) | 0/292 (0.00) | 0/292 (0.00) | 2/292 (0.68) | 0/292 (0.00) | 2/292 (0.68) | 2/292 (0.68) |
| Combined cohorts, N (%) | 0/610 (0.00) | 0/610 (0.00) | 4/610 (0.65) | 0/610 (0.00) | 5/605 (0.83) | 5/610 (0.82) |
| Sample category . | IFN-α2 1 ng/ml . | IFN-β 1 ng/ml . | IFN-ω 1 ng/ml . | IFN-α2 100 pg/ml . | IFN-ω 200 pg/ml . | Individuals with neutralizing autoAbs . |
|---|---|---|---|---|---|---|
| Danish cohort, N (%) | 0/318 (0.00) | 0/318 (0.00) | 2/318 (0.63) | 0/318 (0.00) | 3/313a (0.96) | 3/318 (0.94) |
| American cohort, N (%) | 0/292 (0.00) | 0/292 (0.00) | 2/292 (0.68) | 0/292 (0.00) | 2/292 (0.68) | 2/292 (0.68) |
| Combined cohorts, N (%) | 0/610 (0.00) | 0/610 (0.00) | 4/610 (0.65) | 0/610 (0.00) | 5/605 (0.83) | 5/610 (0.82) |
Five samples excluded based on reduced transfection efficiency.